Uveitis Trial, Recruiting NCT06587828 Sponsor: TScan Therapeutics, Inc. Condition: Uveitis
Back to Uveitis

Uveitis Trial, Recruiting

NCT06587828
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with, or are suspected to have, one of the following conditions: Crohn's disease, ulcerative colitis, celiac disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, multiple sclerosis, scleroderma, systemic sclerosis with lung involvement, or another autoimmune disease (confirm with trial site).
  • You are 18 years old or older at the time you sign the consent form.
  • You are able to understand and willing to sign a consent form agreeing to take part in the study.
  • You are currently taking certain approved treatments for your condition that are not known to directly harm immune cells called T cells, such as anti-inflammatory pain relievers, or specific biological or oral medications used for autoimmune diseases (confirm with trial site for your specific medication).
  • You are a suitable candidate for a biopsy or tissue sample to be taken either during a planned medical procedure where extra material would be used for research, or as a low-risk research-only procedure in the opinion of your doctor.

Who may not be able to join:

  • You are taking certain medications that are known to be harmful to T cells and cannot be stopped for at least 4 weeks before the study, including steroids (such as prednisone or budesonide), sulfasalazine, mesalamine, azathioprine, methotrexate, certain JAK inhibitor tablets, alemtuzumab, cladribine, or teriflunomide — unless a specific exception is approved by the study organisers.
  • You have another illness or condition that your doctor feels would make it unsafe or unsuitable for you to take part in this study.
  • You have dementia, a significantly altered mental state, or a psychiatric condition that would prevent you from understanding and agreeing to take part.
  • You have had a serious or life-threatening allergic reaction to local anaesthetics (such as lidocaine) or to sedation medications that may be used during a biopsy procedure.
  • You are currently pregnant or breastfeeding, due to potential unknown risks to both you and your baby from the study procedures or anaesthetics used.
  • You have any other medical or mental health condition that your treating doctor believes would make taking part in this study unreasonably risky for you.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 857-399-9930

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
TScan Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
3 January 2023
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Identify peptide targets together with their associated TCRs in patients with autoimmune diseases under study.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov